Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
03/2003
03/05/2003EP1286664A2 Method of treating immune pathologies with low dose estrogen
03/05/2003EP1286659A2 Macromolecular drug complexes and compositions containing the same
03/05/2003EP1286658A2 Y-ifn liquid-droplet aerosol and method
03/05/2003EP1286657A1 Nasal ointment based on white petroleum jelly
03/05/2003EP1286590A2 Peptide analogs and mimetics suitable for in vivo use in the treatment of diseases associated with abnormal protein folding into amyloid, amyloid-like deposits or beta-sheet rich pathological precursor thereof
03/05/2003EP1135141A4 Phospholipase inhibitors for the treatment of cancer
03/05/2003EP1131059B1 Dry powder for inhalation
03/05/2003EP1089714B1 Processes to generate particles of water-insoluble compounds of up to 2000 nm in size
03/05/2003EP1069907A4 DIAGNOSIS, PREVENTION AND TREATMENT OF ULCERATIVE COLITIS, AND CLINICAL SUBTYPES THEREOF, USING MICROBIAL UC pANCA ANTIGENS
03/05/2003EP1006798A4 Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
03/05/2003EP0942901B1 Cyclic imines as pesticides
03/05/2003EP0932417B1 Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system
03/05/2003EP0928197B1 Use of proteins as agents against autoimmune diseases
03/05/2003EP0895474A4 Liquid eye drop composition
03/05/2003EP0877795A4 Isolation of precursor cells from hematopoietic and non-hematopoietic tissues and their use
03/05/2003EP0853610B1 Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
03/05/2003EP0845034B1 peptide having pronociceptive properties
03/05/2003EP0835262B1 Method for the treatment of corticosteroid induced osteopenia
03/05/2003EP0830143B1 Use of leukemia inhibitory factor and endothelin antagonists
03/05/2003EP0822827B1 Antagonists of lhrh
03/05/2003EP0804254B1 Heat treated blood plasma proteins
03/05/2003EP0791009A4 Modified neuropeptide y receptors
03/05/2003EP0731688B1 Aerosol drug formulations for use with non-cfc propellants
03/05/2003EP0728143B1 Oncoprotein protein kinase
03/05/2003EP0667784B1 Inhibitors of cell regulatory factors and methods for preventing or reducing scarring
03/05/2003EP0656952B1 Cationic peptides and method for production
03/05/2003EP0602126B1 Immunoglobulin variants for specific fc epsilon receptors
03/05/2003EP0554352B1 A method for transplanting cells into the brain and therapeutic uses therefor
03/05/2003CN1400977A A novel human cell cysle control related protein and a sequence encoding the same
03/05/2003CN1400910A Factor VII or VIIa like molecules
03/05/2003CN1400905A Novel therapeutic use of enoxaparin
03/05/2003CN1400871A Use of glutamate and/or a glutamate precursor for the preparation of a nutritional or pharmaceutical preparation for the treatment or prevention of hyperpermeability of undesired permeability of the
03/05/2003CN1400870A Improved pediatric formula and methods for providing nutrition and improving tolerance
03/05/2003CN1400316A Collapsin reaction medium protein-1
03/05/2003CN1400219A Amino acid polypeptide with strong membrane-inserting capability
03/05/2003CN1400218A Biological active peptide whose sequence number is 19
03/05/2003CN1400217A Biological active peptide whose sequence number is 20
03/05/2003CN1400018A Medicine for curing adiposis, diabetes and related diseases
03/05/2003CN1400017A Medicine for curing asthma disease
03/05/2003CN1102598C Peptides derived from human heat shock protein 60, compositions and application thereof
03/05/2003CN1102408C Stable, aqueous alpha interferon solution formulations
03/05/2003CN1102382C Preparation and methods for the treatment of T cell mediated diseases
03/05/2003CA2421283A1 Novel mmp-2 derivatives for use as inhibitors of integrin .alpha.v.beta.3
03/05/2003CA2356438A1 Use of terpenes and derivatives as potentiators of antitumor agents in the treatment of cancers
03/04/2003WO2002020614A2 Endoglin-specific polypeptide, production and use thereof
03/04/2003US6528699 Inserting nucleic acid construct which comprises promoter, milk protein specific signal sequence; can use for treating diabetes and multiple sclerosis
03/04/2003US6528640 Synthetic ribonucleic acids with RNAse activity
03/04/2003US6528635 Tumor antigen protein, gene thereof, and utilization thereof
03/04/2003US6528634 Aiolos gene
03/04/2003US6528633 Cyclin-selective ubiquitin carrier polypeptides
03/04/2003US6528630 Calcium channel compositions and methods
03/04/2003US6528625 Chemokine Receptor 5 Protein (CCR5 or CKR-5); inhibition of interaction of cell bearing CCR5 with a ligand; inhibiting HIV infection of a cell; use treatment and prevention of HIV
03/04/2003US6528624 Comprising a human IgG Fc region with amino acid substitution at two or more positions; displays altered effector function; C1q binding affinity; complement dependent cytotoxicity
03/04/2003US6528623 Antibodies that specifically bind ACT-4-L-h-1 ligand
03/04/2003US6528619 Cyclic peptide binding inhibitors; structural formulas; use drugs for diseases mediated by urokinase and receptor; tumors; inflammation; angiogenesis
03/04/2003US6528618 Synthetic peptides; serine proteases; human leukocyte elastase; cathepsin G; chronic inflamation conditons; rheumatoid arthritis; pulmonary emphysema; cystic fibrosis; bronchitis; asthma
03/04/2003US6528533 Treating or preventing neuronal damage associated with neurological diseases; hydrazide based compounds containing the group -N-N-CO-X- where X is C,O,S,or N
03/04/2003US6528520 Method of treating the syndrome of coronary heart disease risk factors in humans
03/04/2003US6528514 Pyrimidin-4-one-5-amino-3-alkylcarboxamidomethyl compounds
03/04/2003US6528506 Viability of organs transplants
03/04/2003US6528505 Cyclic amino acid compounds pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
03/04/2003US6528503 Anticoagulants
03/04/2003US6528493 Modulating activity of endogenous protein
03/04/2003US6528489 Mycotoxin derivatives as antimitotic agents
03/04/2003US6528488 Method for treating cystic fibrosis
03/04/2003US6528487 Including GMP-140, ELAM-1, and lymphocyte-homing receptor.
03/04/2003US6528486 Peptide agonists of GLP-1 activity
03/04/2003US6528485 Human growth hormone releasing factor-PEG conjugates; PEG unit is covalently bound to the amino group of Lys21 of SEQ ID NO:1; the hGRF-PEG conjugate does not contain a triazine group
03/04/2003US6528483 Method of producing concentrated non-buffered solutions of fibronectin
03/04/2003US6528482 Receptor activator of NF-κB
03/04/2003US6528481 NG2/HM proteoglycan-binding peptides that home to angiogenic vasculature and related methods
03/04/2003US6528479 Dominant negative mutants of IRS-1 and uses thereof
03/04/2003US6528314 Procedure for specific replacement of a copy of a gene present in the recipient genome by the integration of a gene different from that where the integration is made
03/04/2003US6528313 Production of transgenic animals; targeted replacement of an endogenous gene; genetic trait expression
03/04/2003US6528312 Nuclease inhibitor (G-Actin) or interleukin-10 (IL-10) use improving cell transfection; mixtures; polynucleotides; use gene therapy, vaccines
03/04/2003US6528310 Cancer control
03/04/2003US6528304 Eukaryotic cells expressing at their surface at least an HLA-G isoform and their applications
03/04/2003US6528299 Inhibited by aprotinin; increased activity by calcium ions and/or heparin or related substances; proenzyme; use in therapy or prophylaxis of bleeding events, wound healing, disorders caused by fibrin-containing thrombin
03/04/2003US6528295 Protein phosphatase methylesterase
03/04/2003US6528294 To effect protein phosphorylation; for use in diagnosis and therapy
03/04/2003US6528287 Recombinant human serum transferrins containing peptides for inducing apoptosis in HIV-1 infected cells
03/04/2003US6528284 S-Region Transfer Activity-70 (SRTA-70); can be used as therapeutic agents in immune response modulation
03/04/2003US6528281 DNA encoding human interleukin-11 receptor
03/04/2003US6528270 Methods for identifying compounds for treatment of cell proliferative disorders associated with adaptor protein interactions
03/04/2003US6528263 Identifying a cell expressing protooncogene polypeptide by contacting a nucleic acid with a polynucleotide reagent and detecting its binding; can be used in diagnosis and treatment of cancer
03/04/2003US6528259 Methods for detecting human methylenetetrahydrofolate reductase allelic variants
03/04/2003US6528253 Compositions and methods for diagnosis of ovarian cancer
03/04/2003US6528098 Viricides
03/04/2003US6528093 Sustained-release preparation
03/04/2003US6528060 Therapeutic compounds
03/04/2003US6528059 Specific epitopic regions of thyroid peroxidase (TPO), a thyroid specific membrane autoantigen, have been identified within amino acid residues protein (SEQ ID NO:2), with at least one distinct binding region within TPO located from
03/04/2003US6528055 Polypeptide for use in the diagnosis, treatment and prevention of infections, immune response defects and autoimmune diseases
03/04/2003US6528054 Comprise one or more breast tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a breast
03/04/2003US6528053 Reducing buildup in the blood and normalizing cholesterol and blood pressure, in a mammal. The compositions comprise Morinda citrifolia extract, red wine extract, prune extract, blueberry extract, pomegranate extract, apple extract, and an
03/04/2003US6528050 Polypeptide growth factors, methods of making them, polynucleotides encoding them, antibodies to them, and methods of using them are disclosed. The polypeptides comprise an amino acid segment that is at least 90% identical to residues
03/04/2003US6528038 An immune response directed against Porphyromonas gingivalis. The composition includes a suitable adjuvant and/or acceptable carrier and one substantially purified P. gingivalis immunogen. The immunogen is selected from the group consisting
03/04/2003CA2421202A1 Endoglin-specific polypeptide, production and use thereof
03/04/2003CA1341423C Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
03/01/2003WO2003000027A2 Blocking peptide for inflammatory cell secretion
03/01/2003CA2452123A1 Blocking peptide for inflammatory cell secretion
1 ... 1895 1896 1897 1898 1899 1900 1901 1902 1903 1904 1905 1906 1907 1908 1909 1910 1911 1912 1913 1914 1915 ... 3163